Key Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Key Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$273	Hold	5	–	–	﹤0.01%	705
2026 Q1	$238	Hold	5	–	–	﹤0.01%	665
2025 Q4	$262	Buy	+5	New	+$299	﹤0.01%	508

Other funds holding CRSP

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

KBC Group Brussels, Belgium $46.3B AUM 43.9% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Key Capital Management's CRSP Position: Q2 2026 in Review

Key Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 5 shares worth $273. The position accounts for ﹤0.01% of the portfolio, ranked #705.

Key Capital Management first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 219 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Key Capital Management held 5 shares of CRISPR Therapeutics worth $273 as of Q2 2026.
Key Capital Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Key Capital Management's portfolio in Q2 2026, its #705 holding.
Key Capital Management first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
219 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Key Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.